Osteoporosis

Detailed Overview

Bone remodeling is a continuous process of resorption by osteoclasts and formation by osteoblasts. Osteoporosis occurs when bone resorption outpaces formation. It is clinically silent until a fracture occurs. Hip fractures carry a 1-year mortality rate of up to 20% in the elderly, making osteoporosis a major public health issue.

Epidemiology & Demographics

Affects roughly 10 million Americans, with another 44 million having low bone mass (osteopenia). Most common in postmenopausal women of Caucasian and Asian descent. 1 in 3 women and 1 in 5 men over age 50 will experience an osteoporotic fracture.

Etiological Mechanism

Primary osteoporosis is due to age-related bone loss and estrogen deficiency post-menopause. Secondary osteoporosis is caused by medications or medical conditions.

Primary Causes

Estrogen deficiency removes the inhibition on osteoclast activity. Secondary causes include chronic glucocorticoid use, hyperthyroidism, hyperparathyroidism, hypogonadism, and malabsorption syndromes (celiac).

• Advanced Age & Menopause: Loss of estrogen leads to rapid bone loss in the 5-7 years following menopause.
• Glucocorticoid Therapy: Prednisone >= 5 mg/day for >3 months profoundly suppresses osteoblast activity.
• Low Body Weight: BMI < 20 kg/m2 means less mechanical loading on bones and less peripheral estrogen production.

Estrogen normally stimulates osteoprotegerin (OPG) production by osteoblasts. OPG acts as a decoy receptor for RANKL, preventing it from binding to RANK on osteoclasts. Post-menopause, reduced estrogen leads to lower OPG and higher RANKL expression. This drives excessive osteoclast proliferation, differentiation, and survival. The osteoclasts rapidly resorb trabecular bone, thinning the trabeculae and severing their connections, irreversibly compromising the structural integrity of the bone.

Characteristic Clinical Presentation

• Asymptomatic: Often called a 'silent disease' until a fracture occurs.
• Loss of height: Progressive loss of height (>1.5 inches) over years due to vertebral compression fractures.
• Kyphosis: Development of a stooped posture or 'dowager's hump' from anterior wedging of thoracic vertebrae.
• Back pain: Acute or chronic pain stemming from vertebral fractures.

Physical Examination Signs

• Thoracic kyphosis and loss of standing height compared to historical max.
• Rib-pelvis distance <= 2 fingerbreadths (indicates lumbar fractures).
• Wall-occiput distance > 0 cm (indicates thoracic kyphosis).

• Hip Fractures: High morbidity, requiring surgery. Significant loss of independence and high 1-year mortality.
• Vertebral Compression Fractures: Lead to chronic pain, restrictive lung disease due to kyphosis, and GI compression.
• Colles' Fracture: Distal radius fracture occurring when catching oneself during a fall.

Diagnostic Criteria & Guidelines

Diagnosis is established by: 1) T-score <= -2.5 at the lumbar spine, total hip, or femoral neck by DEXA scan, OR 2) History of low-trauma fracture of the hip or spine, OR 3) T-score between -1.0 and -2.5 with a high FRAX score (10-year probability of major osteoporotic fracture >= 20% or hip fracture >= 3%).

Differential Diagnosis

• Osteomalacia (Vitamin D deficiency)
• Multiple Myeloma
• Primary Hyperparathyroidism
• Paget Disease of Bone

Laboratory Tests & Biomarkers

• Serum Calcium, Phosphorus, Alkaline Phosphatase: Typically completely normal in primary osteoporosis.
• Serum 25-hydroxyvitamin D: Often low (<30 ng/mL); checked to rule out osteomalacia and ensure adequacy before treatment.
• DEXA Scan (Dual-energy X-ray Absorptiometry): Measures BMD. Results are reported as T-scores (compared to healthy young adults) and Z-scores (age-matched).

Imaging Modalities & Findings

• DEXA Scan:
• Thoracolumbar X-ray:

• Normal
  T-score >= -1.0.
• Osteopenia
  T-score between -1.0 and -2.5. Low bone mass.
• Osteoporosis
  T-score <= -2.5, or a history of a fragility fracture regardless of T-score.

Second-Line & Adjunctive Therapy

IV Bisphosphonates (Zoledronic acid 5 mg IV yearly) for oral intolerance. RANKL inhibitor (Denosumab 60 mg SQ every 6 months) for high fracture risk. Anabolic agents (Teriparatide 20 mcg SQ daily or Romosozumab) for very severe osteoporosis (T-score < -3.0 or multiple fractures).

Surgical & Procedural Management

Surgical fixation (ORIF or arthroplasty) for hip fractures. Kyphoplasty or vertebroplasty for acute, painful vertebral compression fractures refractory to medical therapy.

Recommended Lifestyle Changes

• Perform weight-bearing and muscle-strengthening exercises (walking, resistance training).
• Implement fall prevention strategies at home (remove throw rugs, install grab bars, improve lighting).
• Smoking cessation and limiting alcohol intake to <2 drinks per day.

Patient Counseling & Advice

Instructions for oral bisphosphonates: Must take first thing in the morning on an empty stomach with a full glass of plain water, and remain completely upright for 30 minutes to prevent erosive esophagitis and ensure absorption. Warn of rare risks like osteonecrosis of the jaw (ONJ) and atypical femur fractures with long-term use.

Follow-Up & Monitoring Schedule

Repeat DEXA scan every 1 to 2 years to monitor treatment response. Consider a 'drug holiday' after 3-5 years of bisphosphonate therapy if fracture risk has decreased.

Preventive Strategies

Maximizing peak bone mass in youth through adequate nutrition and exercise. Routine DEXA screening for all women >= 65 years and men >= 70 years.

Treatment effectively stops bone density decline and significantly reduces fracture risk by 30-50%. Pre-existing fractures cannot be reversed.